Anti-inflammatory properties of cannabichromene

Wirth, Philip W.; Watson, E.S.; ElSohly, Mahmoud A.; Turner, Carlton E.; Murphy, James C.

doi:10.1016/0024-3205(80)90631-1

Cited by 46 publications

(30 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Cannabinoids have been shown to possess anti-inflammatory effects, [12][13][14][15][16][17][18] but the mechanism of action is not yet known. COX enzyme inhibiting activity has previously been observed for CBD and CBDA.…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have demonstrated anti-inflammatory activities in vivo and in vitro for various cannabinoid compounds, [12][13][14][15][16][17][18] which makes this hypothesis very plausible. Inhibiting effects on COX enzyme activity have also previously been observed for cannabidiol and cannabidiolic acid, 17,19) and cannabinoids have potential to affect the potency of NSAIDs.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa

Ruhaak

Felth

Karlsson

et al. 2011

Biological & Pharmaceutical Bulletin

123

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa

Ruhaak

Felth

Karlsson

et al. 2011

Biological & Pharmaceutical Bulletin

123

View full text Add to dashboard Cite

“…CBC was reported to induce sedation and ataxia in canines (Gaoni et al , 1966); however, subsequent studies failed to replicate these effects (Gaoni et al ., 1971). Of relevance to the present study, CBC and its analogs have been reported to have anti-inflammatory properties in vivo and in vitro (Turner et al , 1981; Wirth et al , 1980a; Wirth et al , 1980b). …”

Section: Introductionmentioning

confidence: 90%

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinol☆

DeLong

Wolf

Poklis

et al. 2010

Drug and Alcohol Dependence

View full text Add to dashboard Cite

In contrast to the numerous reports on the pharmacological effects of Δ 9 -tetrahydrocannabinol (THC), the pharmacological activity of another substituent of Cannabis sativa, cannabichromene (CBC) remains comparatively unknown. In the present study, we investigated whether CBC elicits cannabinoid activity in the tetrad assay, which consists of the following four endpoints: hypomotility, antinociception, catalepsy, and hypothermia. Because cannabinoids are well documented to possess anti-inflammatory properties, we examined CBC, THC, and combination of both phytocannabinoids in the lipopolysaccharide (LPS) paw edema assay. CBC elicited activity in the tetrad that was not blocked by the CB 1 receptor antagonist, rimonabant. Moreover, a behaviorally inactive dose of THC augmented the effects of CBC in the tetrad that was associated with an increase in THC brain concentrations. Both CBC and THC elicited dose-dependent anti-inflammatory effects in the LPSinduced paw edema model. The CB 2 receptor, SR144528 blocked the anti-edematous actions of THC, but not those produced by CBC. Isobolographic analysis revealed that the anti-edematous effects of these cannabinoids in combination were additive. Although CBC produced pharmacological effects, unlike THC, its underlying mechanism of action did not involve CB 1 or CB 2 receptors. In addition, there was evidence of a possible pharmacokinetic component in which CBC dose-dependently increased THC brain levels following an i.v. injection of 0.3 mg/kg THC. In conclusion, CBC produced a subset of behavioral activity in the tetrad assay and reduced LPS- To whom correspondence should be addressed: Aron H. Lichtman. Tel: (804) 828-8480; Fax (804) 828-2117; alichtma@vcu.edu. Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.Contributors G.T. DeLong conducted the bulk of the studies, analysis of data, and writing of the manuscript. C.E. Wolf contributed to the laboratory procedures for analytical studies. A. Poklis contributed to the design of the analytical studies. A.H. Lichtman oversaw the study, along with contributing to the writing of the manuscript. Conflict of InterestNone of the authors report a conflict of interest that could have influenced, or be perceived to influence, this work. NIH Public Access NIH-PA Author ManuscriptNIH-PA Author Manuscript NIH-PA Author Manuscript induced paw edema through a noncannabinoid receptor mechanism of action. These effects were augmented when CBC and THC were co-administered.

show abstract

“…Gizakietan bere efektu isolatua deskribatu gabe dagoen arren, animalietan zenbait eragin egotzi zaizkio. Batetik, arratoietan CBCak hantura periferikoa inhibi dezake [46]. Izan ere, CB 1 hartzaileekiko afinitate altua ez badu ere, CB 2 hartzaileari afinitate handiagoz lotzen zaio [32].…”

Section: Beste Kannabinoide Batzuk: Kannabikromenoa Kannabinoide Ahaunclassified

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Aostri

Pineda

Mendiguren

2017

EKAIA

View full text Add to dashboard Cite

Laburpena:Cannabis sativa landarean kannabidiola, kannabigerola edo Δ 9 -tetrahidrokannabibarina bezalako kannabinoide ez-psikoaktiboak aurki daitezke. Oro har, kannabinoide horiek kannabinoideen hartzaileekiko (CB) afinitate txikia dutenez, ez daukate kannabinoide klasikoek (bereziki Δ 9 -THCak) duten aktibitate psikoaktiboa. Gizakietan eta animalietan kannabinoide ez-psikoaktiboekin egindako lehenengo ikerketek horien propietate terapeutikoak frogatu dituzte. Efektu horiek azaltzeko itu eta mekanismo desberdinak proposatu dira, besteak beste, hartzaile serotonergikoen aktibazioa edota entzima desberdinen modulazioa.Hitz gakoak: kannabidiola, kannabigerola, Δ 9 -tetrahidrokannabibarina, kannabinoide, 5-HT 1A hartzailea. Abstract:Cannabis sativa plant contains non-psychoactive phytocannabinoids including cannabidiol, cannabigerol or Δ 9 -tetrahydrocannabivarin. Unlike classical cannabinoids (i.e Δ 9 -THC) most of these compounds bind with low affinity to cannabinoid receptors (CB), which seems to be the reason for their lack of psychoactive effect. Preliminary studies performed in humans and animals demonstrated that these cannabinoids have therapeutic properties. Different targets and mechanisms have been proposed to explain their effects such as activation of serotonergic receptors or modulation of different enzymes.

show abstract

Anti-inflammatory properties of cannabichromene

Cited by 46 publications

References 9 publications

Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa

Evaluation of the Cyclooxygenase Inhibiting Effects of Six Major Cannabinoids Isolated from Cannabis sativa

Pharmacological evaluation of the natural constituent of Cannabis sativa, cannabichromene and its modulation by Δ9-tetrahydrocannabinol☆

Kannabinoide berriak: segurtasun eta eraginkortasun terapeutikoaren bila

Contact Info

Product

Resources

About